Physician profile
Aimee Brown
NPI 1427456193
$1,573.99
in general payments reported to CMS, 2019-2025
28 companies · $726 in 2025
The $726 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $129 · 2023: $259 · 2024: $459 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.08 |
| Education | $141.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $236.67 | 2024-2025 | Xt Cdx |
| Pfizer INC. | $206.90 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $179.04 | 2024-2025 | Opdivo |
| Seagen INC. | $139.41 | 2022-2023 | Tukysa |
| Merck Sharp & Dohme LLC | $94.67 | 2023-2025 | Keytruda, Lynparza |
| Abbvie INC. | $89.21 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $70.75 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $47.48 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $45.14 | 2023-2024 | Imfinzi |
| Sanofi-Aventis U.S. LLC | $41.99 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $37.37 | 2025 | Onivyde |
| Eisai INC. | $36.53 | 2025 | |
| Astellas Pharma US INC | $34.65 | 2025 | Veozah |
| Lilly USA, LLC | $33.04 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Aveo Pharmaceuticals, INC. | $26.00 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $24.48 | 2022 | |
| Genmab U.S., INC. | $23.92 | 2024 | Epkinly |
| Alnylam Pharmaceuticals INC. | $23.51 | 2024 | Givlaari |
| Incyte Corporation | $22.42 | 2024 | Pemazyre, Monjuvi |
| Stemline Therapeutics INC. | $21.20 | 2024 | Orserdu |
| Beigene USA, INC. | $19.98 | 2023 | Brukinsa |
| Gilead Sciences, INC. | $18.91 | 2024 | |
| Novo Nordisk INC | $18.35 | 2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $18.34 | 2025 | Zejula, Jemperli |
| Janssen Biotech, INC. | $17.99 | 2024 | Rybrevant |
| Amgen INC. | $16.09 | 2023 | Lumakras |
| Daiichi Sankyo INC. | $15.45 | 2023 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.